Thursday, 19 September 2019

Top 20 survey: Industry Crosses $173 Billion

03 July 2014 | Analysis | By BioSpectrum Bureau

This is the seventh edition of the BioSpectrum Asia Pacific Bioscience Industry Survey

This is the seventh edition of the BioSpectrum Asia Pacific Bioscience Industry Survey

Singapore: The bioscience industry in the major markets of the Asia-Pacific region excluding Japan and comprising Australia, China, India, South Korea, Malaysia, Singapore, and Taiwan recorded a 12 percent growth in 2013. The total bioscience revenues in 2013 stood at $173.64 billion, compared to the $154.40 billion sales figure by end of December 2012. The industry's growth in 2013 was marginally higher at 12 percent compared to the previous year's growth of 11 percent. The growth has been driven by China, despite the Chinese pharma market encountering several changes. China registered 22 percent growth. Malaysia and Singapore also registered double digit growth of 12 percent and 48 percent respectively, while India, Australia, and South Korea witnessed low single digit growth.

• Public listed companies cross $100 billion mark for the first time

• Industry registers 12 percent growth

• Top 20 companies still account for nearly 60 percent market share

One of the main features of this year's survey is that all the players in the list of Top 20 companies have crossed the $1 billion sales revenue. This is good news as the number of billion dollar companies is swelling in Asia Pacific - as result of both organic growth and inorganic growth strategies via mergers, acquisitions, and joint ventures.

 

China and India, which are the two important markets in the region account for the lion's share of the total market. In fact, the two countries have increased their market share from 52 percent of the overall revenue of $111 billion in 2009 to 75 percent in 2013. The market share rose from 72 percent in 2012 to 75 percent in 2013. China was the No 1 country with $87 billion in revenue and India stood second at $40 billion. Australia-New Zealand were No 3, South Korea No 4, Taiwan No 5, Malaysia and Singapore at No 6.

The total revenue of the 320 publicly listed companies account for 58.56 percent of the overall revenue of $173.64 billion. China's publicly listed companies crossed the $50 billion mark for the first time. India was a distant second with $25.9 billion revenue.

1
Bioscience Industry Growth in Asia-Pacific (2007-2013)

 

2
Bioscience Industry in Asia-Pacific (2007-2013)


The Top 5 companies by revenue in 2013 were Sinopharm (China), CSL (Australia), China National Accord Medicines Corporation (China), Sigma Pharmacauticals (Australia), and Sun Pharma (India). China Accord Medicines Corporation moved to the third spot in this year's survey from the fourth position in 2013, while Sun Pharma raced to the fifth rank. The top five accounted for 30 percent share in the overall revenue of public listed companies with total revenue of $37.4 billion.

 

3
Bioscience Industry* Growth (By Country)

4
Bioscience Industry* Pie (By Country)

• China contributes almost 50 percent of total revenue by public listed companies


• India is No 2 with three percent growth and Australia No 3 with one percent growth

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Pharma innovation getting inhibited in APAC?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls